Welcome to PakSearch.com Pakistan's Premier Business Information
Service


For business information, annual reports, laws, ordinances, regulations and articles.




Google
 
Web Paksearch.com
Parke, Davis & Company Limited
Annual Report 2000
Contents
COMPANY INFORMATION
NOTICE OF MEETING
REPORT OF THE DIRECTORS
AUDITORS' REPORT TO MEMBERS
BALANCE SHEET
PROFIT AND LOSS ACCOUNT
CASH FLOW STATEMENT
STATEMENT OF CHANGES IN EQUITY
NOTICE OF THE ACCOUNTS
LOCATION MAP
Company Information
BOARD OF DIRECTORS M. Raziuddin Ansari
Chairman, Chief Executive
and Managing Director
Irtiza Husain
Badaruddin F. Vellani
Dr. Amjad Waheed
Abdul Majeed
Adil Zaman
Syed Arif Masood
COMPANY SECRETARY Abdul Majeed
AUDITORS Taseer Hadi Khalid & Co.
Chartered Accountants
BANKERS American Express Bank Limited
Citibank, N.A.
Standard Chartered Bank
Muslim Commercial Bank Limited
National Bank of Pakistan
REGISTERED OFFICE B-2, S. I. T. E.,
& FACTORY Karachi-75700
Notice of Meeting
Notice is hereby given that the 40th Annual General Meeting of the Company will be held at B-2, S.I.T.E.,
Karachi, on Monday, April 30, 2001 at 10:00 a.m. to transact the following business:
1. To consider, and if deemed appropriate, to approve the audited Balance Sheet of the Company as at
December 31, 2000 and the Profit and Loss Account for the year ended December 31, 2000 as well as the
Reports of the Directors and Auditors of the Company thereon.
2. To consider, and if deemed appropriate, to approve the payment of dividend of the Company for the year
ended December 31, 2000 as recommended by the Directors of the Company.
3. To appoint the Auditors of the Company and to fix their remuneration.
By Order of the Board
ABDUL MAJEED
Company Secretary & Director
Karachi: April 2, 2001
NOTES:
1. The Share Transfer Books of the Company will be closed from April 23, 2001 to April 30, 2001
(both days inclusive).
2. A member entitled to attend, speak and vote at the Annual General Meeting may appoint a proxy to attend
and vote on his behalf. Proxies in order to be effective must be received at the Registered Office of the
Company not less than 48 hours before the Meeting. The proxy must be a member of the Company, except
that a corporation being a member of the Company may appoint as its proxy one of the officers or some
other person though not a member of the Company.
3. Members are requested to notify us immediately of any change in their Registered Address currently
available with us.
4. The Registered Office of the Company is located at B-2, S.I.T.E, Karachi.
Report of the Directors
We are pleased to present your Company's Annual Report together with the audited accounts for the year ended
December 31, 2000. Prior year's figures of Profit and Loss Account are for the thirteen months period ended
December 31, 1999.
BUSINESS REVIEW
This year saw the first price increase after a lapse of three and a half year. The Ministry of Health allowed an 8%
price increase on controlled drugs and a 10% price increase on decontrolled products. However, the devaluation
of 10% in the Pak Rupee- US Dollar parity soon after the announcement of the much awaited price increase
eroded its positive impact. We have utilised our internal efficiencies and aggressive cost containment drives to
successfully meet the challenges posed by the operating environment.
Despite the difficult economic situation, the net sales for the year under review grew to Rs. 1,006 million
reflecting a growth of 12% over last year. If the extraordinary event of the corporate restructuring is not taken in
account, the Company's profit before tax increased to Rs. 149 million reflecting a growth of 29%. The corporate
restructuring whereby severance packages of about Rs.45 million were required to be paid to those employees who
took early retirement resulted in a diluted profit before tax of Rs. 104 million. This restructuring was necessary to
ensure long term savings and will enable the Company to reduce its administration costs, and enhance its
competitiveness and long term viability.
The products of the Company have shown improved market share. The Company introduced LIPITOR ®
(atorvastatin), a cholesterol reducer, towards the end of the year which generated sales of Rs. 19 million. Our high
volume products, including PONSTAN ® (mefanamic acid) and BENADRYL ® (dyphenhydramine) cough
syrup, have shown consistent growth over last year volumes.
FINANCIAL RESULTS
Results for 2000 together with Directors' recommendations for appropriations are given below:
Rs. 000
Profit after taxes 65,097
Add: Unappropriated profit brought forward 370
-----------
65,467
Less: Transfer to general reserve 36,000
-----------
Balance available for appropriation 29,467
Recommended dividend ~ 150% 29,376
-----------
Unappropriated profit carried forward 91
==========
DIVIDEND
The Directors recommend a cash dividend of 150% for the year ended December 31, 2000.
FUTURE PROSPECTS
The future performance of your Company is dependent on the economic conditions in the country and the
Government's policies towards the pharmaceutical industry. The pharmaceutical industry continues to be highly
regulated. The registration process requires to be made more transparent and the patented products require to be
protected. However, the present Government's policy towards deregulation, privatisation and increasing the export
potential of local products augurs well for the economy.
The Company has a pool of highly skilled, dedicated, and competent manpower. Our product portfolio is
diversified, competitively priced and we have some excellent products which are soon to be launched in the
Pakistan market. We have been investing regularly over the years in order to modemise our manufacturing
facilities, and to make them environmentally friendly and quality oriented. As a result of pursuing policies and
processes that reflect our commitment to a clean and green environment, your Company achieved ISO 14001
certification, thus becoming the first pharmaceutical company in Pakistan to achieve this distinction.
Future prospects of your Company remain good if the investor friendly policies announced by the Government are
implemented and the economic conditions in the country stabilise as a consequence.
SUBSEQUENT EVENTS
After the end of the financial year of the Company under review, the Board of Directors considered the most
expedient manner of fully utilising the benefits accruing from the fact that Pfizer Laboratories Limited ("PLL")
and the Company have, become associated companies. The synergies which are likely to arise upon the
amalgamation of the two Companies, have led the Directors to resolve that a scheme of arrangement be prepared
for the merger of the two Companies for consideration by the Board. In this connection, the Directors have
appointed Taseer Hadi Khalid & Co. to undertake the valuation of the Company as at December 31, 2000. A
similar exercise is being undertaken for the valuation of PLL. On the basis of such valuation, the swap ratio of the
shares of the two companies will be determined.
PLL has applied to the Ministry of Health (MOH) for allowing its products to be toll manufactured at the
manufacturing facility of the Company. In case the approval is granted by MOH, a Toll Manufacturing Agreement
will be executed between the two companies.
EMPLOYEES
A service agreement was executed between PLL and the Company w.e.f. June 19, 2000, in order to enable the
employees of both the companies to work together and for the two associated companies to utilise their synergies
for their economic benefit. The common utilisation of the sales staff and the field force of both the companies will
enable the Company to enjoy the benefits of economies of scale and sharing of costs. By virtue of this agreement
the Company will get the benefit (at cost) of the services provided by PLL employees.
Any company is ultimately only as strong as its human resources and we have been fortunate to have highly
motivated, skilled and committed employees. Your Company has achieved good results in the year under review
despite a challenging economic environment in the country.
We would like to express our sincere appreciation to our employees at all levels, as without their dedication and
hard work these results would not have been possible.
A two year agreement was successfully negotiated between the workers' union (CBA) and the Company. This
agreement will expire on December 31, 2002.
Total number of employees at December 31, 2000 was 349.
BOARD OF DIRECTORS
During August 2000 Mr. M. Saleem and Mr. S. Khalid Hussain resigned from the Board and the resulting
vacancies were filled in by the appointments of Mr. Abdul Majeed and Mr. Adil Zaman respectively. In March
2001, Mr. Ramesh Thadani resigned from the Board and the resulting vacancy was filled in by the appointment of
Mr. Syed Arif Masood.
While welcoming the new appointees the Board wishes to record its appreciation of the contributions made by the
outgoing Directors to the business operations of the Company.
PARENT COMPANY
The Company's holding company is Parke Davis & Company, USA, a subsidiary of Pfizer Inc., a company
incorporated in the United States of America.
As mentioned in our half yearly report, during June 2000, Pfizer Inc., a company incorporated in the United States
of America, acquired Warner-Lambert Company also incorporated in the United States of America. Parke Davis &
Company, of the USA which holds 75.6% of the issued shares in the capital of Parke, Davis & Company, Limited,
Pakistan, is a wholly owned subsidiary of Warner-Lambert Company, USA. As a consequence of the above change
the ultimate holding company of Parke, Davis & Company, Limited, Pakistan is now Pfizer Inc., USA.
AUDIT REPORT/ACCOUNTS
The format of the Audit Report for the current year is different from that issued last year and has been
necessitated by the issuance of SRO No. 597 (1)/2000 dated August 25, 2000, by the Securities and Exchange
Commission. This notification provides for the Auditors Report to be given as per the new format.
Current years tax provisions is based on normal tax regime. However from 2001 and onwards, the Company has
opted for the presumptive tax regime and accordingly the deferred tax liability at December 31, 2000, has been
reversed.
The Capital Project Appropriations (CPA) relates to the refurbishment/enhancement of the office of the Company.
EARNINGS PER SHARE
The after-tax earnings per ordinary share of Rs. 10 is Rs. 33.25.
PATTERN OF SHAREHOLDING
The pattern of share holding is attached with this report.
AUDITORS
The auditors Messrs. Taseer Hadi Khalid & Co., Chartered Accountants, retire at the conclusion of the Annual
General Meeting and being eligible offer themselves for re-appointment.
On behalf of the Board
M. Raziuddin Ansari
Karachi: April 2, 2001 Chairman
Pattern of holding of shares
Pattern of holding of shares held by the shareholders of Parke, Davis & Company, Limited as at
December 31, 2000.
NUMBER OF SHAREHOLDING TOTAL
SHAREHOLDERS FROM TO SHARES HELD
92 1 -- 100 8,665
39 101 -- 500 11,565
19 501 -- 1000 16,200
10 1001 -- 5000 26,900
4 5001 -- 10000 29,500
2 10001 -- 15000 28,000
1 70001 -- 75000 75,000
1 280001 -- 285000 282,270
1 1480001 -- 1485000 1,480,300
----------- -----------
169 1,958,400
========== ==========
CATEGORIES OF - Shares
SHAREHOLDERS Number Held Percentage
INDIVIDUALS 158 89,830 4.58
INVESTMENT COMPANIES 2 284,770 14.54
INSURANCE COMPANIES 1 75,000 3.83
JOINT STOCK COMPANIES 5 1,506,600 76.93
FINANCIAL INSTITUTIONS 1 2,000 0.10
MODARABA COMPANIES 1 100 0.01
CO-OPERATIVE SOCIETIES 1 100 0.01
----------- ----------- -----------
169 1,958,400 100.00
========== ========== ==========
Auditors' Report to the Members
We have audited the annexed balance sheet of Parke, Davis & Company, Limited as at 31 December 2000 and the related
profit and loss account, cash flow statement and statement of changes in equity together with the notes forming part thereof,
for the year then ended and we state that we have obtained all the information and explanations which, to the best of our
knowledge and belief, were necessary for the purposes of our audit.
It is the responsibility of the company's management to establish and maintain a system of internal control, and prepare and
present the above said statements in conformity with the approved accounting standards and the requirements of the
Companies Ordinance, 1984. Our responsibility is to express an opinion on these statements based on our audit.
We conducted our audit in accordance with the auditing standards as applicable in Pakistan. These standards require that we
plan and perform the audit to obtain reasonable assurance about whether the above said statements are free of any material
misstatement. An audit includes examining, on a test basis, evidence supporting the amounts and disclosures in the above said
statements. An audit also includes assessing the accounting policies and significant estimates made by management, as well
as, evaluating the overall presentation of the above said statements. We believe that our audit provides a reasonable basis for
our opinion and, after due verification, we report that:
a) in our opinion, proper books of account have been kept by the company as required by the Companies
Ordinance, 1984;
b) in our opinion:
i) the balance sheet and profit and loss account together with the notes thereon have been drawn up
in conformity with the Companies Ordinance, 1984, and are in agreement with the books of
account and are further in accordance with accounting policies consistently applied.
ii) the expenditure incurred during the year was for the purpose of the company's business; and
iii) the business conducted, investments made and the expenditure incurred during the year were in
accordance with the objects of the company;
c) in our opinion and to the best of our information and according to the explanations given to us, the balance
sheet, profit and loss account, cash flow statement and statement of changes in equity together with the notes
forming part thereof conform with approved accounting standards as applicable in Pakistan and give the
information required by the Companies Ordinance, 1984, in the manner so required and respectively give a
true and fair view of the state of the company's affairs as at 31 December 2000 and of the profit, its cash
flows and changes in equity for the year then ended; and
d) in our opinion Zakat deductible at source under the Zakat and Ushr Ordinance, 1980 (XVIII of 1980), was
deducted by the company and deposited in the Central Zakat Fund established under section 7 of
that Ordinance.
The financial statements for the thirteen months period ended 31 December 1999 were audited by another firm
of auditors.
Date: 19 March 2001 Taseer Hadi Khalid & Co.
Karachi Chartered Accountants
BALANCE SHEET
As at 31 December 2000
Note 2000 1999
(Rupees'000)
SHARE CAPITAL AND RESERVES
Share capital
Authorised
4,000,000 ordinary shares of Rs. 10 each 40,000 40,000
========== ==========
Issued, subscribed and paid-up 3 19,584 19,584
General reserve - revenue 4 604,000 568,000
Unappropriated profit 91 370
------------ ------------
623,675 587,954
DEFERRED LIABILITIES
Staff retirement benefits 5 31,963 17,151
Deferred taxation 6 -- 8,675
CURRENT LIABILITIES
Running finance under mark-up arrangements 7 202 4,976
Creditors, accrued and other liabilities 8 151,480 160,093
Proposed dividend 29,376 34,272
------------ ------------
181,058 199,341
CONTINGENCIES AND COMMITMENTS 9
------------ ------------
836,696 813,121
========== ==========
FIXED ASSETS - TANGIBLE
Operating assets 10 215,326 234,474
Capital work-in-progress 11 11,186 16,825
------------ ------------
226,512 251,299
LONG-TERM LOANS 12 2,423 1,958
LONG-TERM DEPOSITS 1,955 1,812
CURRENT ASSETS
Spares 13 12,960 131,131
Stock-in-trade 14 233,617 2,319,991
Trade debts 15 207,254 122,937
Loans and advances 16 3,128 5,904
Deposits and short-term prepayments 17 22,535 25,663
Other receivables 18 3,156 3,127
Taxation - payments less provision 39,705 31,740
Cash and bank balances 19 83,451 123,569
------------ ------------
605,806 558,052
------------ ------------
836,696 813,121
========== ==========
The annexed notes form an integral part of these accounts.
M. Raziuddin Ansari Abdul Majeed
Chairman & Chief Executive Director
PROFIT AND LOSS ACCOUNT
for the year ended 31 December 2000
Note Year ended Thirteen months
31 December period ended
2000 31 December
1999
(Rupees'000)
Sales 20 1,006,360 972,143
Cost of sales 21 678,826 666,415
----------- -----------
327,534 305,728
Administration and selling expenses 22 235,934 183,893
----------- -----------
Operating profit 91,600 121,835
Other income 23 17 809 15,763
----------- -----------
109,409 137,598
Financial charges 24 2,287 2,778
Other charges 25 2,700 9,252
----------- -----------
4,987 12,030
----------- -----------
Profit before taxation 104,422 125,568
Taxation 26
- Current year 480,001 44,701
- Deferred (8,675) 3,147
----------- -----------
39,325 47,848
----------- -----------
Profit after taxation 65,097 77,720
Unappropriated profit brought forward 370 797
----------- -----------
Profit available for appropriation 65,467 78,517
Appropriations
Dividend at Rs. 3 per share out of 1998 profit -- 5,875
Proposed final dividend at Rs. 15 per share
(1999: Rs. 17.50 per share) 29,376 34,272
----------- -----------
29,376 40,147
Transfer to general reserve 36,000 38,000
----------- -----------
65,376 78,147
----------- -----------
Unappropriated profit carried forward 91 370
========== ==========
Earnings per share - basic and diluted 27 33.25 39.69
========== ==========
The annexed notes form an integral part of these accounts.
M. Raziuddin Ansari Abdul Majeed
Chairman & Chief Executive Director
CASH FLOW STATEMENT
for the year ended 31 December 2000
Note Year ended Thirteen months
31 December period ended
2000 31 December
1999
(Rupees'000)
CASH FLOW FROM OPERATING ACTIVITIES
Cash generated from operations 31 59,235 233,189
Financial charges paid (619) (2,374)
Taxes paid (55,965) (49,463)
----------- -----------
Net cash flows from operating activities 2,651 181,352
CASH FLOW FROM INVESTING ACTIVITIES
Fixed capital expenditure (10,287) (33,703)